Introduction: Renal cell carcinoma (RCC) is the most common type of kidney cancer in
adults, and its pathogenesis is strictly related to altered cellular response to hypoxia, in …

Background Everolimus is an approved agent for use after disease progression with
vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in …

Background Data are limited regarding routine use of everolimus after initial vascular
endothelial growth factor (VEGF)–targeted therapy. The aim of this prospective …

Aim To assess the efficacy and safety of everolimus in patients with metastatic renal cell
carcinoma (mRCC) who failed one or two anti-VEGF therapies. Patients and methods Data …

INTRODUCTION: In the phase III RECORD-1 trial (ClinicalTrials. gov: NCT00410124),
patients with metastatic renal cell carcinoma (mRCC) who progressed on previous vascular …

Purpose Renal cell carcinoma (RCC) is the most common renal tumor and accounts for
nearly 3% of adult cancers. In the recent years, seven new targeted agents have been …

Abstract Background Two mTOR inhibitors, TEM and EVE, proved to be active in mRCC but
have never been compared in a prospective trial. We aimed to compare their effectiveness …

Background: Everolimus is approved for treatment of anti-vascular endothelial growth factor
(VEGF)-refractory patients with metastatic renal cell carcinoma (mRCC). Clinical trials rarely …

Background RECORD-1 demonstrated clinical benefit of everolimus in patients with
metastatic renal cell carcinoma (mRCC) previously treated with sunitinib, sorafenib, or both; …

Introduction: The efficacy of sequential everolimus (RAD001, Afinitor®), an orally
administered inhibitor of mammalian target of rapamycin (mTOR), is one of the therapeutic …